Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Nomograms Predictive of Recurrence in Malignant Tumors Treated With Skull Base Surgery: An International Collaborative Study.

Head & neck·2026

Same author

Integrating computational evaluation and mechanical testing to optimize laser-sintered polyether ketone scaffolds for mandibular reconstruction in large animal models.

Journal of the mechanical behavior of biomedical materials·2026

Same author

Agentic AI for Spatial Omics.

Immunology and cell biology·2026

Same author

The Impact of Margin Status Following Surgery for Metastatic Cutaneous Squamous Cell Carcinoma to the Parotid Gland.

Head & neck·2026

Same author

A Randomised Controlled Trial Comparing Spray Versus Paint Application of Iodine Skin Antisepsis in Head and Neck Surgery.

ANZ journal of surgery·2026

Same author

Evaluation of bone formation within β-tricalcium phosphate scaffolds in a sheep scapular bioreactor model using micro-computed tomography analysis.

Regenerative biomaterials·2026

Search research articles

Related Experiment Video

Updated: Sep 14, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using

Rahul Ladwa^1,2, Jenny H Lee³, Margaret McGrath¹

¹Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

|July 21, 2025

Summary

Pembrolizumab shows promise for treating cutaneous squamous cell carcinoma (cSCC). This neoadjuvant immunotherapy achieved high complete response rates, potentially allowing patients to avoid surgery and radiotherapy.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Related Experiment Videos

Last Updated: Sep 14, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Area of Science:

Oncology
Immunotherapy
Dermatology

Background:

Cutaneous squamous cell carcinoma (cSCC) presents a significant treatment challenge.
Neoadjuvant immunotherapy is emerging as a strategy to improve outcomes.
High pathologic complete response (pCR) rates suggest potential for treatment de-escalation.

Purpose of the Study:

To evaluate pembrolizumab's efficacy in resectable cutaneous squamous cell carcinoma (cSCC).
To assess the potential for risk-adapted, surgery- and radiotherapy-free management.
To reduce treatment-related morbidity in patients with cSCC.

Main Methods:

A phase II, multicenter study involving patients with resectable stage II-IV (M0) cSCC.
Pembrolizumab administered for four cycles prior to 18F-FDG-PET assessment.
Clinical complete response (cCR) allowed for total de-escalation; pCR allowed for partial de-escalation.

Main Results:

A combined clinical or pathologic complete response (cpCR) was achieved in 63% of patients (17/27).
Total de-escalation (no surgery/radiotherapy) in 48%; partial de-escalation in 15%.
No recurrence observed in patients with cpCR at 18-month median follow-up; low grade ≥3 adverse events (7%).

Conclusions:

Pembrolizumab demonstrated a high cpCR rate in resectable cSCC.
The findings support pembrolizumab's potential to enable avoidance of surgery and radiotherapy.
This approach may reduce treatment morbidity for cSCC patients.